Tirofiban With Endovascular Therapy for Blocked Brain Arteries From Atherosclerosis
Tests tirofiban added to clot removal in adults with acute stroke from atherosclerosis.
Plain-language title generated from the registry record
Registry title: Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large brain artery, narrowed by plaque, who are going to have clot-removal treatment (EVT). After the procedure they get tirofiban or a placebo.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stroke symptoms within 24 hours of last known well. Stroke severity score (NIHSS) of 6 or more. Early brain scan score (ASPECTS) of 6 or more. Blockage in the internal carotid artery, the M1 part of the middle cerebral artery, the V4 part of the vertebral artery, or the basilar artery. Remaining narrowing of 50% or more without planned angioplasty or stenting.
- Earlier treatment
- The care team plans to do endovascular thrombectomy (EVT). Before the trial, people must not have had tirofiban or another GP IIb/IIIa inhibitor.
Main reasons for not taking part
- Bleeding in the brain seen on scans before randomization
- Bleeding problems, such as low platelets, or recent blood thinner use, or recent bleeding or major surgery
- Any source of clots from the heart, such as atrial fibrillation
- Pregnancy or breastfeeding at admission
- Severe kidney problems
Read by machine on 12 November 2026.
Where in China
- Beijing Anzhen Hospital Affiliated to Capital Medical UniversityBeijing, ChinaContact: Xiaochuan Huo, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07026318
- Record updated
- 22 September 2025
- Original description
This randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to receive either tirofiban or matching placebo after EVT. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhagewithin 48 hours after randomization.Read full original descriptionShow less
Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke: A Multicenter, Prospective, Double-blind, Vehicle-controlled, Randomized Controlled Trial
This randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to receive either tirofiban or matching placebo after EVT. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhagewithin 48 hours after randomization.
Inclusion: Age ≥18 years; Pre-stroke modified Rankin Scale (mRS) score of 0-1; Acute ischemic stroke symptoms present within 24 hours of last known well time; Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6; Anterior circulation: Alberta Stroke Program Early CT Score (ASPECTS) ≥6 Posterior circulation: pc-ASPECTS ≥6; Occlusion of intracranial internal carotid artery (ICA), M1 segment of middle cerebral artery (MCA), V4 segment of vertebral artery, or basilar artery; Clinical care team plans to perform endovascular thrombectomy (EVT); Subject or legally authorized representative can provide informed consent; Residual stenosis ≥50% without planned angioplasty/stenting.
Exclusion: Intracranial hemorrhage confirmed by imaging prior to randomization, or major intracranial hemorrhage on intraprocedural flat-panel CT; Tirofiban or other GP IIb/IIIa inhibitor use before randomization or other GP IIb/IIIa inhibitor used post treatment; Gastrointestinal or genitourinary bleeding within 30 days post-stroke onset, or major surgery within 14 days; Pre-existing neurological/psychiatric conditions that may confound assessment; Any confirmed cardioembolic source (including atrial fibrillation, valvular disease, intracardiac thrombus, recent MI, cardiomyopathy with EF <30%, etc.); Bleeding diathesis including coagulopathy (platelets <100×10⁹/L, aPTT >50s, or INR >2.0), DOAC use within 48 hours, or history of HIT; Severe renal insufficiency (GFR <30mL/min or Scr >220μmol/L [2.5mg/dL]); Pregnancy or lactation at admission; Contraindications to radiographic contrast agents, nickel, titanium or their alloys; Life expectancy <6 months; Arterial tortuosity or anomalies preventing device delivery; Unlikely to complete 90-day follow-up.